60 Degrees Pharmaceuticals Partners with Runway Health to Expand ARAKODA Access for Malaria Prevention
Key Insights
60 Degrees Pharmaceuticals (search) announced a partnership with Runway Health (search) to provide international travelers direct access to ARAKODA through a telehealth platform starting April 2, 2026.
ARAKODA (tafenoquine) is the only FDA-approved, broad-spectrum, once-weekly malaria (search) prevention option available to international travelers in the United States.
The partnership enables eligible users to match their travel itinerary with personalized medical treatment plans designed by U.S. licensed healthcare providers through online consultations.
60 Degrees Pharmaceuticals (search) announced a strategic partnership with Runway Health (search) to expand pre-departure access to ARAKODA (tafenoquine) for malaria (search) prevention among international travelers through a direct-to-patient telehealth platform. The collaboration, set to commence April 2, 2026, represents a significant expansion of the company's marketing strategy for the only FDA-approved, broad-spectrum, once-weekly malaria prevention option available in the United States.
Partnership Details and Market Access
The partnership adds a travel-focused consumer telehealth platform to 60 Degrees Pharma's ARAKODA marketing strategy, offering new convenience to people planning travel to malaria (search)-endemic regions. Runway Health (search)'s platform enables adults to access physician-led online consultations before traveling to regions where malaria may be prevalent, with seamless home delivery of prescribed medication arriving before departure.
Eligible users can match their travel itinerary with personalized medical treatment plans designed by U.S. licensed healthcare providers through the Runway Health (search) platform. This direct-to-consumer approach addresses the critical need for accessible malaria (search) prevention among the growing population of international travelers.
ARAKODA's Unique Market Position
ARAKODA represents a significant advancement in malaria (search) prophylaxis, offering the only broad-spectrum, once-weekly prescription malaria prevention option on the U.S. market. The drug's active ingredient, tafenoquine, was discovered by Walter Reed Army Institute of Research and approved for malaria prophylaxis in 2018 in the United States and Australia.
According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, approximately 16 days, offers potential advantages in less-frequent dosing for malaria (search) prophylaxis. The safety of the approved regimen has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months.
Clinical Significance and Global Health Impact
Malaria (search), caused by the bite of the Anopheles mosquito, remains one of the most serious, life-threatening infectious diseases worldwide. It poses a constant threat to those living in malaria-endemic regions and to international travelers visiting those areas. If left untreated, malaria can progress to severe malaria, which is often fatal.
The prescribed regimen for ARAKODA involves 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel.
Safety Profile and Contraindications
ARAKODA is indicated for malaria (search) prophylaxis in patients aged 18 years and older but carries important contraindications. The drug should not be administered to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or unknown G6PD status, as G6PD testing must be performed before prescribing due to the risk of hemolytic anemia (search).
Additional contraindications include breastfeeding when the infant is G6PD deficient or has unknown G6PD status, patients with a history of psychotic disorders (search) or current psychotic symptoms, and those with known hypersensitivity reactions to tafenoquine or other 8-aminoquinolines.
The most common adverse reactions with incidence greater than or equal to 1 percent include headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase, motion sickness, insomnia, depression, abnormal dreams, and anxiety.
Market Response and Commercial Strategy
Following the partnership announcement, 60 Degrees Pharmaceuticals (search) shares surged 179.50% to $5.61, reflecting strong investor confidence in the expanded market access strategy. The company, founded in 2010 and headquartered in Washington, D.C., specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne diseases.
ARAKODA is currently commercially available in both the United States and Australia through pharmaceutical wholesaler networks and retail pharmacies as a prescription-only malaria (search) prevention drug. The partnership with Runway Health (search) represents a strategic expansion into the direct-to-consumer telehealth market, potentially increasing accessibility for travelers who may face barriers to traditional healthcare consultations before international travel.